BridgeMD
A randomized trial of multi-factorial primary prevention in high risk subjects candidate to a lung cancer early detection CT program
EU CTIS ID: 2024-513660-26-00
What this study is testing
The main objective of the study is to evaluate the efficacy of multi-factor intervention in high risk subjects in terms of inflammatory inflammation.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age between 55 and 75 years
- Heavy smoker
- Eligibility to screening with annual chest CT
- Availability and ability to use the Internet via PC, tablet or smartphone
- Ability to understand the project to which you intend to participate
- No tumors in the last 5 years
You likely can't join if
- Hypersensitivity to acetylsalicylic acid, salicylates or any of the excipients (excipients: cellulose powder, corn starch; coating: copolymers of methacrylic acid, sodium lauryl sulfate, polysorbate 80, talc, triethyl citrate)
- Serious psychiatric problems
- Abuse of alcohol or other substances (even before)
- Chronic treatment with cardioASA, or other anti-clotting or anti-coagulant drugs (for example: heparin, dicumarol)
- Treatment with methotrexate
- Existing Mastocytosis
See the full eligibility criteria
- Age between 55 and 75 years
- Heavy smoker
- Eligibility to screening with annual chest CT
- Availability and ability to use the Internet via PC, tablet or smartphone
- Ability to understand the project to which you intend to participate
- No tumors in the last 5 years
- Signature of informed consent for enrollment in the study and for the processing of personal data
- Hypersensitivity to acetylsalicylic acid, salicylates or any of the excipients (excipients: cellulose powder, corn starch; coating: copolymers of methacrylic acid, sodium lauryl sulfate, polysorbate 80, talc, triethyl citrate)
- Serious psychiatric problems
- Abuse of alcohol or other substances (even before)
- Chronic treatment with cardioASA, or other anti-clotting or anti-coagulant drugs (for example: heparin, dicumarol)
- Treatment with methotrexate
- Existing Mastocytosis
- History of asthma induced by the administration of salicylates or substances to similar activity, particularly non-steroidal antiinflammatory drugs
- Gastroduodenal ulcer
- Hemorrhagic diathesis
- Severe chronic pathology (eg: severe respiratory and / or renal and / or hepatic and / or cardiac insufficiency)
- Severe kidney failure
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.